

JC20 RECEIVED 01 NOV 2005

PTO/IS/06a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10555860
				Filing Date	Concurrently Herewith
				First Named Inventor	Christopher P. Holmes
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	04279/100M213-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-4,179,337	12-18-1979	Davis et al.	
	AB*	US-6,113,906	09-08-2000	Greenwald, R.B. et al	
	AC*	US-20020015691-A1	02-07-2002	Greenwald et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>2</sup> -Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
	BA	WO-92/16555	10-01-1992	Enzion, Inc.		
	BB	WO-96/40772	12-19-1996	Johnson & Johnson		
	BC	WO-96/40750	12-19-1996	Glaxo Group Ltd.		
	BD	WO-96/40189	12-19-1996	Glaxo Group Ltd.		
	BE	WO-98/25965	06-18-1998	Glaxo Group Ltd.		
	BF	WO-00/24770	05-04-2000	Amgen, Inc.		
	BG	WO-00/24782	05-04-2000	Amgen, Inc.		
	BH	WO-00/33881	06-15-2000	Debio Rech Pharma S.A.		
	BI	WO-02/065988	08-29-2002	Enzion, Inc.		
	BJ	WO-2004/014424	02-19-2004	Enzion, Inc.		
	BK	WO-2004/101600	11-25-2004	Affymax, Inc.		
	BL	WO-2004/101606	11-25-2004	Affymax, Inc.		
	BM	WO-2004/101611	11-25-2004	Affymax, Inc.		
	BN	WO-2004/108070	12-16-2004	Enzion, Inc.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST-16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>4</sup>
	CA	Wrighton et al., "Increased Potency of an Erythropoietin Peptide Mimetic Through Covalent Dimerization." Nature Biotechnology, Nature Publishing, US, Vol. 15, (11-1-1997).			
	CB	Greenwald et al., "Effective drug delivery by PEGylated drug conjugates." Advanced Drug Delivery Reviews. Amsterdam, NL. Vol. 55, N. 2, Pages 217-250 (02-10-2003).			
	CC	Greenwald et al., "Controlled release of proteins from their poly(ethylene glycol) conjugates: Drug delivery systems employing 1,6-elimination." Bioconjugate Chemistry. Vol. 14, No. 2, Pages 395-403 (04-03-2003).			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Andrew D. Kosar/	Date Considered	10/23/2009
--------------------	-------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ADK/